CD14 is a decision-maker between Fas-mediated death and inflammation.

IF 7.5 1区 生物学 Q1 CELL BIOLOGY Cell reports Pub Date : 2024-08-29 DOI:10.1016/j.celrep.2024.114685
Zoie Magri, David Jetton, Hayley I Muendlein, Wilson M Connolly, Hunter Russell, Irina Smirnova, Shruti Sharma, Stephen Bunnell, Alexander Poltorak
{"title":"CD14 is a decision-maker between Fas-mediated death and inflammation.","authors":"Zoie Magri, David Jetton, Hayley I Muendlein, Wilson M Connolly, Hunter Russell, Irina Smirnova, Shruti Sharma, Stephen Bunnell, Alexander Poltorak","doi":"10.1016/j.celrep.2024.114685","DOIUrl":null,"url":null,"abstract":"<p><p>Signaling through classical death receptor Fas was mainly appreciated as a pro-death pathway until recent reports characterized pro-inflammatory outcomes of Fas-mediated activation in pathological contexts. How Fas signaling can switch to pro-inflammatory activation is poorly understood. Herein, we report that in macrophages and neutrophils, the Toll-like receptor (TLR) adapter CD14 determines the inflammatory output of Fas-mediated signaling. Our findings propose CD14 as a crucial chaperone of Fas receptor internalization in macrophages and neutrophils, resulting in Cd14<sup>-/-</sup> myeloid cells that are protected from FasL-induced apoptosis, activate nuclear factor κB (NF-κB), and release cytokines in response. As in TLR signaling, CD14 is also required for Fas to signal through the adaptor TRIF (TIR-domain-containing adapter-inducing interferon-β) and induce a pro-death complex. Our findings demonstrate that CD14 availability can determine the switch between Fas-mediated pro-death and pro-inflammatory outcomes by internalizing the receptor.</p>","PeriodicalId":9798,"journal":{"name":"Cell reports","volume":null,"pages":null},"PeriodicalIF":7.5000,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cell reports","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1016/j.celrep.2024.114685","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CELL BIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Signaling through classical death receptor Fas was mainly appreciated as a pro-death pathway until recent reports characterized pro-inflammatory outcomes of Fas-mediated activation in pathological contexts. How Fas signaling can switch to pro-inflammatory activation is poorly understood. Herein, we report that in macrophages and neutrophils, the Toll-like receptor (TLR) adapter CD14 determines the inflammatory output of Fas-mediated signaling. Our findings propose CD14 as a crucial chaperone of Fas receptor internalization in macrophages and neutrophils, resulting in Cd14-/- myeloid cells that are protected from FasL-induced apoptosis, activate nuclear factor κB (NF-κB), and release cytokines in response. As in TLR signaling, CD14 is also required for Fas to signal through the adaptor TRIF (TIR-domain-containing adapter-inducing interferon-β) and induce a pro-death complex. Our findings demonstrate that CD14 availability can determine the switch between Fas-mediated pro-death and pro-inflammatory outcomes by internalizing the receptor.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CD14 是 Fas 介导的死亡和炎症之间的决策者。
通过经典死亡受体 Fas 发出的信号主要被认为是一种促进死亡的途径,直到最近有报道称 Fas 介导的激活在病理情况下产生了促炎结果。人们对 Fas 信号如何转换为促炎激活还知之甚少。在此,我们报告了在巨噬细胞和中性粒细胞中,Toll 样受体(TLR)适配器 CD14 决定了 Fas 信号介导的炎症输出。我们的研究结果表明,CD14 是巨噬细胞和中性粒细胞中 Fas 受体内化的关键伴侣,导致 Cd14-/- 髓样细胞免受 FasL 诱导的细胞凋亡的影响,激活核因子 κB(NF-κB),并释放细胞因子作为响应。与 TLR 信号转导一样,CD14 也是 Fas 通过适配体 TRIF(含 TIR 域的适配体诱导干扰素-β)发出信号并诱导促死亡复合物所必需的。我们的研究结果表明,CD14 的可用性可通过使受体内化来决定 Fas 介导的促死亡和促炎症结果之间的转换。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cell reports
Cell reports CELL BIOLOGY-
CiteScore
13.80
自引率
1.10%
发文量
1305
审稿时长
77 days
期刊介绍: Cell Reports publishes high-quality research across the life sciences and focuses on new biological insight as its primary criterion for publication. The journal offers three primary article types: Reports, which are shorter single-point articles, research articles, which are longer and provide deeper mechanistic insights, and resources, which highlight significant technical advances or major informational datasets that contribute to biological advances. Reviews covering recent literature in emerging and active fields are also accepted. The Cell Reports Portfolio includes gold open-access journals that cover life, medical, and physical sciences, and its mission is to make cutting-edge research and methodologies available to a wide readership. The journal's professional in-house editors work closely with authors, reviewers, and the scientific advisory board, which consists of current and future leaders in their respective fields. The advisory board guides the scope, content, and quality of the journal, but editorial decisions are independently made by the in-house scientific editors of Cell Reports.
期刊最新文献
Integrative identification of non-coding regulatory regions driving metastatic prostate cancer Cross-regulations of two connected domains form a mechanical circuit for steady force transmission during clathrin-mediated endocytosis Dynamic phosphorylation of FOXA1 by Aurora B guides post-mitotic gene reactivation Multi-trait analysis reveals risk loci for heart failure and the shared genetic etiology with blood lipids, blood pressure, and blood glucose Diribonuclease activity eliminates toxic diribonucleotide accumulation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1